<DOC>
	<DOCNO>NCT01372163</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability PF-05190457 administration multiple dose healthy volunteer Type 2 diabetic patient evaluate plasma drug concentration multiple dos .</brief_summary>
	<brief_title>A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male female nonchildbearing potential age 18 55 year , BMI 18.5 30.5 kg/m^2 , weight 50 100 kg , inclusive . Type 2 diabetic male female nonchildbearing potential age 18 55 year , BMI 18.5 40.0 kg/m^2 , weight 50 150 kg , HbA1c 7.010.0 % , inclusive . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease . Additionally , type 2 diabetic patient history diabetic complication significant endorgan damage pharmacologic treatment diabetes addition metformin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Multiple Ascending Doses</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Type 2 Diabetic Patients</keyword>
</DOC>